- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07937865
Early Intervention for Postpartum PTSD: Comparing Written Exposure and Capnometry-Guided Breathing Therapy - Phase 2
Early Intervention for Postpartum PTSD: Comparing Written Exposure and Capnometry Guided Breathing Therapy - Phase 2
The purpose of this study is to evaluate the feasibility, acceptability, and preliminary effectiveness of two early interventions, Written Exposure Therapy (WET) and Capnometry-Guided Breathing Intervention (CGRI), for reducing post-traumatic stress disorder (PTSD) symptoms following childbirth, compared with usual care.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Arkansas
-
Little Rock, Arkansas, Forenede Stater, 72205
- University of Arkansas for Medical Sciences
-
Kontakt:
- Heather Moody
- Telefonnummer: 501-526-4333
- E-mail: HLMoody@uams.edu
-
-
California
-
Palo Alto, California, Forenede Stater, 94304
- Stanford University
-
Kontakt:
- Guillermina Ferrea
- Telefonnummer: (650) 457 7704
- E-mail: gferrea@stanford.edu
-
Kontakt:
- Aleesha Jethwa
- Telefonnummer: +44 7857 907762
- E-mail: Ajethwa1@stanford.edu
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Age ≥18
- Delivered a live infant within 5 days
- Severe maternal morbidity or infant admitted to NICU
- PCL-5 ≥28
- English-speaking
- Able to consent and participate
Exclusion Criteria:
- Active psychosis or mania
- Current suicidal crisis
- Current suicidal intent or plan
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Written Exposure Therapy (WET)
Participants will complete 5 writing sessions. One 50-minute session will be held in the hospital before discharge, followed by four 50-minute sessions by secure video once a week. Sessions are delivered by a trained study therapist under licensed clinician supervision. |
Participants will complete 5 writing sessions. One 50-minute session will be held in the hospital before discharge, followed by four 50-minute sessions by secure video once a week. Sessions are delivered by a trained study therapist under licensed clinician supervision. |
|
Eksperimentel: Capnometry-Guided Breathing Intervention (CGRI)
Participants will complete one 45-minute in-hospital training session using the device, which includes a tablet and breathing sensor. They will then practice guided breathing at home twice daily for about 17 minutes each time for 4 weeks, with weekly phone check-ins from study staff. |
Participants will complete one 45-minute in-hospital training session using the device, which includes a tablet and breathing sensor. They will then practice guided breathing at home twice daily for about 17 minutes each time for 4 weeks, with weekly phone check-ins from study staff. |
|
Ingen indgriben: Postpartum Standard of Care
Participants will follow their current standard of care. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Procentdel af deltagere, der gennemfører Written Exposure Therapy (WET)
Tidsramme: Baseline til uge 6
|
Baseline til uge 6
|
|
|
Procentdel af overholdelse af Skriftlig Eksponeringsterapi (WET)
Tidsramme: Baseline til uge 6
|
Baseline til uge 6
|
|
|
Procentdel af deltagere, der gennemfører Capnometri-guidet respiratorisk intervention (CGRI)
Tidsramme: Baseline til uge 6
|
Baseline til uge 6
|
|
|
Procentvis overholdelse af Kapnometristyret Respiratorisk Intervention (CGRI)
Tidsramme: Baseline til uge 6
|
Baseline til uge 6
|
|
|
Percentage of participants initiating assigned treatment
Tidsramme: Baseline (up to 2 weeks)
|
Proportion of participants who begin their assigned intervention (≥1 session for WET; completion of initial training for CGRI) |
Baseline (up to 2 weeks)
|
|
Participant Satisfaction Scale Score using Client Satisfaction Questionnaire (CSQ-8)
Tidsramme: Week 5
|
Participant satisfaction measured using the CSQ-8 questionaire, an 8-item scale. (Scale score 8 - 32. Higher scores represent greater satisfaction with treatment.) |
Week 5
|
|
Treatment credibility using the Opinion About Treatment (OAT) form
Tidsramme: Week 5
|
Participant perceptions of treatment credibility will be measured using the OAT form. (Scale score 3 - 27. Higher scores represent greater perceived credibility of the intervention.) |
Week 5
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change from baseline in PTSD Checklist for DSM-5 (PCL-5) Scale Score
Tidsramme: Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 12
|
Change in PTSD symptoms during past week measured by the PTSD Checklist for DSM-5 (PCL-5), a 20-item self-report measure. (Score range 0 - 80, higher scores indicating greater severity of PTSD symptoms.). |
Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 12
|
|
Change from baseline in Edinburgh Postnatal Depression Scale (EPDS) Scale Score
Tidsramme: Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 12
|
Participants complete the EPDS questionnaire, a 10-item scale assessing postpartum depressive symptoms over the past 7 days. (Score range 0 - 30, higher scores represents greater symptom severity.) |
Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 12
|
|
Change from baseline in Whole Person Health Index (WPHI) Scale Score
Tidsramme: Baseline, Week 3, Week 6, Week 12
|
Participants complete WHPI questionaire, a 9 item scale assessing global health and functioning. (Score range 9 - 81, higher scores represent better health). |
Baseline, Week 3, Week 6, Week 12
|
|
Change from baseline in Generalized Anxiety Disorder Questionaire (GAD-7)
Tidsramme: Baseline, Week 3, Week 6, Week 12
|
Participants complete the GAD-7, a 7-item scale assessing anxiety symptoms over 2 weeks. (Score range 0 - 21, higher scores represent greater anxiety severity.) |
Baseline, Week 3, Week 6, Week 12
|
|
Change from baseline in Maternal-infant bonding (MIBS) Scale Score
Tidsramme: Baseline, Week 3, Week 6, Week 12
|
Participants complete the MIBS questionaire, an 8 item measure of bonding difficulties over the past few weeks (Score range 0 - 24, higher scores represent greater bonding impairment). |
Baseline, Week 3, Week 6, Week 12
|
|
Change from baseline in STanford Obstetric Recovery checKlist (STORK) scale score
Tidsramme: Baseline, Week 3, Week 6, Week 12
|
Participants complete the STORK questionnaire, a 47-item scale assessing postpartum recovery over the past 7 days. (Score range 0 - 188, higher score represents a greater degree of recovery) |
Baseline, Week 3, Week 6, Week 12
|
|
Change from baseline in Breastfeeding Self-Efficacy Scale-Short Form (BFSES-SF)
Tidsramme: Baseline, Week 3, Week 6, Week 12
|
Participants complete the BFSES-SF, a 14-item measure of breastfeeding self-efficacy (Score range 14 - 70, higher scores indicate greater breastfeeding confidence.) |
Baseline, Week 3, Week 6, Week 12
|
|
Percentage of participants completing hair sample collection at Baseline and Week 6
Tidsramme: Baseline, Week 6
|
Participants have hair samples collected at baseline and at Week 6 post treatment. |
Baseline, Week 6
|
|
Change in hair cortisol concentration between Baseline and Week 6
Tidsramme: Baseline, Week 6
|
Participants have hair samples collected at baseline and at Week 6 post treatment. Hair steroid concentrations reflect average systemic hormone exposure over the preceding weeks. Change in hair cortisol concentration from Baseline to Week 6 |
Baseline, Week 6
|
|
Change in hair cortisone concentration between Baseline and Week 6
Tidsramme: Baseline, Week 6
|
Participants have hair samples collected at baseline and at Week 6 post treatment. Hair steroid concentrations reflect average systemic hormone exposure over the preceding weeks. Change in hair cortisone concentration from Baseline to Week 6 |
Baseline, Week 6
|
|
Change in hair testosterone concentration between Baseline and Week 6
Tidsramme: Baseline, Week 6
|
Participants have hair samples collected at baseline and at Week 6 post treatment. Hair steroid concentrations reflect average systemic hormone exposure over the preceding weeks. Change in hair testosterone concentration from Baseline to Week 6 |
Baseline, Week 6
|
|
Change in hair progesterone concentration between Baseline and Week 6
Tidsramme: Baseline, Week 6
|
Participants have hair samples collected at baseline and at Week 6 post treatment. Hair steroid concentrations reflect average systemic hormone exposure over the preceding weeks. Change in hair progesterone concentration from Baseline to Week 6 |
Baseline, Week 6
|
|
Change in hair corticosterone concentration between Baseline and Week 6
Tidsramme: Baseline, Week 6
|
Participants have hair samples collected at baseline and at Week 6 post treatment. Hair steroid concentrations reflect average systemic hormone exposure over the preceding weeks. Change in hair corticosterone concentration from Baseline to Week 6 |
Baseline, Week 6
|
|
Change in hair dehydroepiandrosterone (DHEA) concentration between Baseline and Week 6
Tidsramme: Baseline, Week 6
|
Participants have hair samples collected at baseline and at Week 6 post treatment. Hair steroid concentrations reflect average systemic hormone exposure over the preceding weeks. Change in hair dehydroepiandrosterone (DHEA) concentration values from Baseline to Week 6 |
Baseline, Week 6
|
|
Change in hair androstenedione concentration between Baseline and Week 6
Tidsramme: Baseline, Week 6
|
Participants have hair samples collected at baseline and at Week 6 post treatment. Hair steroid concentrations reflect average systemic hormone exposure over the preceding weeks. Change in hair androstenedione concentration from Baseline to Week 6 |
Baseline, Week 6
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Pervez Sultan, Stanford University
- Ledende efterforsker: Debra Kaysen, Stanford University
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 80498-2
- R01AT013866-01 (U.S. NIH-bevilling/kontrakt)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).
IPD-delingstidsramme
Beginning 9 months and ending 36 months following article publication.
IPD-delingsadgangskriterier
Wish whom? Investigators whose proposed use of the data has been approved by an independent review committee ("learned intermediary") identified for this purpose. For what types of analysis? For individual participant data meta-analysis By what mechanism will data be made available? Proposals may be submitted up to 36 months following article publication. After 36 months the data will be available in our University's data warehouse but without investigator support other than deposited metadata. Information regarding submitting proposals and accessing data may be found at (Link to be provided).
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .